Oral antifibrotics require high systemic dosing to achieve lung exposure, driving toxicity, discontinuation, and limiting the feasibility of combination therapy.
eSpraye is addressing that bottleneck with dry-powder inhaled fixed-dose combinations, co-forming multiple APIs into a single 1–5 μm particle delivered directly to the lung. The approach enables:
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
